UBS Group started coverage on shares of Illumina (NASDAQ:ILMN) in a report released on Tuesday, 99wallstreet.com reports. The firm issued a neutral rating and a $340.00 price target on the life sciences company’s stock.
Several other analysts have also issued reports on the company. Morgan Stanley upped their target price on Illumina from $195.00 to $210.00 and gave the stock an underweight rating in a research note on Friday, July 13th. Cowen upped their target price on Illumina from $315.00 to $400.00 and gave the stock a positive rating in a research note on Thursday, September 6th. BidaskClub lowered Illumina from a strong-buy rating to a buy rating in a research note on Thursday, October 4th. Argus set a $372.00 target price on Illumina and gave the stock a buy rating in a research note on Friday, August 10th. Finally, ValuEngine raised Illumina from a buy rating to a strong-buy rating in a research note on Tuesday, July 31st. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Illumina presently has a consensus rating of Buy and an average target price of $324.76.
Shares of ILMN opened at $321.69 on Tuesday. The company has a market capitalization of $53.96 billion, a price-to-earnings ratio of 80.40, a PEG ratio of 3.04 and a beta of 0.97. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. Illumina has a 1 year low of $198.21 and a 1 year high of $372.61.
Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.32. The business had revenue of $830.00 million during the quarter, compared to analyst estimates of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. Illumina’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.82 earnings per share. Sell-side analysts anticipate that Illumina will post 5.46 earnings per share for the current fiscal year.
In other news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $351.66, for a total transaction of $1,160,478.00. Following the completion of the sale, the director now owns 392,204 shares of the company’s stock, valued at $137,922,458.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $331.39, for a total value of $3,313,900.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 52,483 shares of company stock valued at $17,702,063. Insiders own 0.54% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Kaizen Advisory LLC boosted its stake in shares of Illumina by 161.0% during the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after purchasing an additional 227 shares during the period. Moneta Group Investment Advisors LLC boosted its stake in shares of Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 9,345 shares during the period. Sun Life Financial INC boosted its stake in shares of Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after purchasing an additional 241 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Illumina by 3,192.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after acquiring an additional 415 shares during the period. Finally, Hall Laurie J Trustee lifted its stake in Illumina by 189.5% in the second quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock worth $154,000 after acquiring an additional 360 shares during the period. 89.84% of the stock is owned by hedge funds and other institutional investors.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.